2022 full-year results highlights

1. Nikita Khadse, Scientist,
R&D, Waltham, Massachusetts
Bradd Roberts, Scientist,
Analytical Science, Waterford, Ireland
With ten consecutive quarters
of growth, the progress we’ve made
in the past three years speaks
for itself. As we launch the next phase
of our strategy, our continued
commitment to investing
in the science will be crucial to
maintaining a steady-state cadence
of first and best in class medicines.
Paul Hudson
Chief Executive Officer, Sanofi
For further information on full-year 2022 results
and definitions of financial indicators, please refer
to the press release issued on February 3, 2023 at:
www.sanofi.com/en/investors
Company sales and business EPS*
Sales by global business unit
Sales by geography
** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.
Full-year 2022
company sales**
€42,997m
+7.0% (+13.9%)
€8.26
+17.1% (+25.9%)
* Earnings per share
Full-year 2022
business EPS**
€9,999m
Europe
€18,275m
US
€14,723m
Rest of
the World
€16,457m
Specialty Care
€14,231m
General Medicines
€5,080m
Consumer Healthcare
€7,229m
Vaccines
Full-year
2022 results
Latest regulatory milestones in Europe
Microglia
Approval
of first and
only treatment
indicated for
prurigo
nodularis
Approval
of our
next-generation
booster
vaccine for
the prevention
of COVID-19
in adults
First
approval
worldwide of
our new solution
for the prevention
of respiratory
syncytial virus
disease
in infants
Approval
of new treatment
for adult patients
with cold
agglutinin
disease
@Sanofi @Sanofi @Sanofi @SanofiaventisTVen